RETN and breast cancer: Based on the ROC curve (Figure 2), serum resistin cutoff value ≥ 737.6 ng/L can be used as a cutoff point at which 83.3% of breast cancer patients (T1 and T2 stages) can be early diagnosed correctly, but 2.5% of normal subjects are false positive.